




A Subgroup Analysis Explored Nivolumab Use for Advanced Renal Cell Carcinoma in Japanese Patients

Janna Afanasjeva, PharmD, BCPS


March 1, 2021



The Presentation Will Describe a Subgroup Analysis of the CheckMate 025 Study



The Presentation Will Describe a Subgroup Analysis of the CheckMate 025 Study



7 Targeted Therapies Were Available for Advanced Renal Cell Carcinoma in Japan (2016)

Tyrosine kinase
inhibitors

Sorafenib
Sunitinib
Axitinib
Pazopanib


Mammalian target of
rapamycin (mTOR)
inhibitors

Everolimus
Temsirolimus

Programmed death-1
(PD-1) immune
checkpoint inhibitor


Nivolumab

Certain Factors Affect the Efficacy and Safety of Targeted Therapies in Asia




Goal: To compare the efficacy and safety of nivolumab versus everolimus in Japanese patients (subgroup analysis from the CheckMate 025 study)


The Presentation Will Describe a Subgroup Analysis of the CheckMate 025 Study




The Subgroup Analysis Compared Nivolumab Versus Everolimus




The Subgroup Analysis Compared Nivolumab Versus Everolimus



The Study Enrolled Patients Diagnosed With Advanced Renal Cell Carcinoma



Endpoints Focused on Survival and Safety



Different Statistical Methods Analyzed Data

Kaplan-Meier method

- OS, PFS, duration of response

Brookmeyer and Crowley method

- OS


Unstratified Cox model

- OS and PFS for nivolumab versus everolimus


Clopper and Pearson method

- ORRs


The Presentation Will Describe a Subgroup Analysis of the CheckMate 025 Study




Japanese Patients Represented Less Than 10% of Total Patients in Each Group




Median Overall Survival Was Not Reached by the Japanese Population




Nivolumab Increased Objective Response Rate




Progression-Free Survival Rates Were Similar Between the Nivolumab and Everolimus Groups



Japanese Patients in the Everolimus Group Reported More Treatment-Related Adverse Events





Nivolumab May Improve Response Rate and Adverse Event Profile in Japanese Patients with Advanced Renal Cell Carcinoma Compared With Everolimus